---
schema_version: "secwatch.filing_event.v1"
accession: "0001585364-26-000040"
form_type: "8-K"
ticker: "PRGO"
cik: "0001585364"
company_name: "PERRIGO Co plc"
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:53:39.639731+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perrigo completes sale of Dermacosmetics business for €305.6M upfront, plus contingent €27M

## Summary
- Upfront cash €305.6M (incl. €5.6M working capital); up to €27M contingent on net sales milestones over three years.
- Brands sold: ACO, Biodermal, Emolium, Iwostin; business generated ~€120M net sales (~5% of adj. op income) in 2025.
- Net proceeds will be used primarily for debt reduction, enhancing financial flexibility and strengthening balance sheet.
- Divestiture is part of Perrigo's Three-S plan to Stabilize, Streamline, and Strengthen the Company.

## SEC filing metadata
- accession: 0001585364-26-000040
- form_type: 8-K
- ticker: PRGO
- cik: 0001585364
- company_name: PERRIGO Co plc
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000040/0001585364-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000040/prgo-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001585364-26-000040
- JSON: https://secwatch.observer/filing/0001585364-26-000040.json
- Plain text: https://secwatch.observer/filing/0001585364-26-000040.txt

## Key facts
- M&A Transactions
  PERRIGO Co plc completed a disposition involving Karo Healthcare AB for €305.6 million in upfront cash plus up to €27.0 million contingent consideration (closed 2026-04-30).
  - Action: disposition
  - Counterparty: Karo Healthcare AB
  - Consideration: €305.6 million in upfront cash plus up to €27.0 million contingent consideration
  - Closing: 2026-04-30
  source text: On April 30, 2026, the Transaction closed pursuant to the terms of the Agreement. In connection with the closing of the Transaction, Karo made a cash payment to the Company of €305.6 million, including €5.6 million in net working capital adjustments. In addition, the Company may be entitled to additional contingent cash consideration of up to €27.0 million upon
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000040/0001585364-26-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.